📊 OCGN Key Takeaways
Is Ocugen, Inc. (OCGN) a Good Investment?
Ocugen exhibits critical financial distress with negative stockholders' equity of -$12.2M, indicating technical insolvency. The company is burning $57M in annual operating cash flow against only $18.6M in liquid assets and $4.4M in revenue, implying less than 4 months of operational runway. Deteriorating net income trends (-25.5% YoY) combined with massive operating losses ($62.9M) and tightening liquidity (1.06x current ratio) signal imminent financial crisis without immediate capital injection or material business development.
Ocugen shows minimal revenue against extremely negative margins and sustained operating losses, resulting in negative stockholders’ equity and very weak interest coverage. Continued heavy cash burn with limited cash on hand makes the business highly dependent on external financing or near-term monetization to remain viable. While revenue grew modestly and EPS losses narrowed, the balance sheet and cash flow profile indicate elevated solvency and dilution risk.
Why Buy Ocugen, Inc. Stock? OCGN Key Strengths
- Maintains $18.6M in cash providing short-term liquidity runway
- Revenue showing modest growth of 8.8% YoY despite small base
- Minimal insider selling pressure indicated by single Form 4 filing in 90 days
- Modest YoY revenue growth (+8.8%) from a low base
- Low capital expenditure requirements support financial flexibility
- EPS loss narrowed YoY
OCGN Stock Risks: Ocugen, Inc. Investment Risks
- Negative stockholders' equity of -$12.2M represents technical insolvency with liabilities exceeding assets by $12.2M
- Operating cash burn of $57M annually against $18.6M cash balance indicates critical solvency risk within 4 months without additional financing
- Current ratio of 1.06x and long-term debt of $27.5M present acute liquidity crisis risk with minimal debt service coverage
- Net income losses deteriorating 25.5% YoY while minimal revenue base of $4.4M cannot sustain $62.9M operating losses
- Negative operating cash flow for extended period indicates structural inability to fund operations from business activities
- Negative stockholders’ equity and leverage elevate solvency risk
- Severe operating losses and FCF burn; interest coverage deeply negative
- High dependence on external financing; dilution/going‑concern risk
Key Metrics to Watch
- Quarterly cash balance and monthly burn rate trajectory
- Debt restructuring announcements or new equity financing completion
- Revenue inflection points and gross margin achievement from product commercialization
- Clinical trial advancement, regulatory approvals, or partnership announcements for revenue catalysts
- Operating cash flow (burn rate)
- Cash & equivalents
Ocugen, Inc. (OCGN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Ocugen, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
OCGN Profit Margin, ROE & Profitability Analysis
OCGN vs Healthcare Sector: How Ocugen, Inc. Compares
How Ocugen, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ocugen, Inc. Stock Overvalued? OCGN Valuation Analysis 2026
Based on fundamental analysis, Ocugen, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ocugen, Inc. Balance Sheet: OCGN Debt, Cash & Liquidity
OCGN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ocugen, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.09 indicates the company is currently unprofitable.
OCGN Revenue Growth, EPS Growth & YoY Performance
OCGN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.1M | -$11.9M | N/A |
| Q2 2025 | $1.1M | -$11.9M | N/A |
| Q1 2025 | $1.0M | -$11.9M | N/A |
| Q3 2024 | $1.1M | -$11.7M | N/A |
| Q2 2024 | $485.0K | -$11.9M | $-0.04 |
| Q1 2024 | $443.0K | -$11.9M | $-0.05 |
| Q1 2019 | N/A | -$9.4M | N/A |
| Q3 2018 | N/A | -$6.0M | $-0.23 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ocugen, Inc. Dividends, Buybacks & Capital Allocation
OCGN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ocugen, Inc. (CIK: 0001372299)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OCGN
What is the AI rating for OCGN?
Ocugen, Inc. (OCGN) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are OCGN's key strengths?
Claude: Maintains $18.6M in cash providing short-term liquidity runway. Revenue showing modest growth of 8.8% YoY despite small base. ChatGPT: Modest YoY revenue growth (+8.8%) from a low base. Low capital expenditure requirements support financial flexibility.
What are the risks of investing in OCGN?
Claude: Negative stockholders' equity of -$12.2M represents technical insolvency with liabilities exceeding assets by $12.2M. Operating cash burn of $57M annually against $18.6M cash balance indicates critical solvency risk within 4 months without additional financing. ChatGPT: Negative stockholders’ equity and leverage elevate solvency risk. Severe operating losses and FCF burn; interest coverage deeply negative.
What is OCGN's revenue and growth?
Ocugen, Inc. reported revenue of $4.4M.
Does OCGN pay dividends?
Ocugen, Inc. does not currently pay dividends.
Where can I find OCGN SEC filings?
Official SEC filings for Ocugen, Inc. (CIK: 0001372299) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OCGN's EPS?
Ocugen, Inc. has a diluted EPS of $-0.09.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is OCGN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Ocugen, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is OCGN stock overvalued or undervalued?
Valuation metrics for OCGN: ROE of N/A (sector avg: 15%), net margin of -1,537.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy OCGN stock in 2026?
Our dual AI analysis gives Ocugen, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OCGN's free cash flow?
Ocugen, Inc.'s operating cash flow is $-57.0M, with capital expenditures of $185.0K. FCF margin is -1,295.0%.
How does OCGN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,537.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.06 (avg: 2).